세계의 지카 바이러스 치료제 시장

Global Zika Virus Therapeutics Market to Reach US$23.9 Billion by 2030

The global market for Zika Virus Therapeutics estimated at US$18.3 Billion in the year 2023, is expected to reach US$23.9 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2023-2030. Acetaminophen, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$14.9 Billion by the end of the analysis period. Growth in the NSAIDs segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.8 Billion While China is Forecast to Grow at 3.8% CAGR

The Zika Virus Therapeutics market in the U.S. is estimated at US$4.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 3.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Zika Virus Therapeutics Market - Key Trends and Drivers Summarized

Why Is Zika Virus Therapeutics Gaining Global Importance?

Zika virus therapeutics are gaining attention due to the increasing incidence of Zika outbreaks, particularly in tropical and subtropical regions, and the severe health complications associated with the virus, including microcephaly in newborns and neurological conditions in adults. The Zika virus is primarily transmitted through mosquitoes, but it can also spread through blood transfusions and sexual contact, making it a significant public health concern. While no specific antiviral treatment for Zika exists yet, research into developing therapeutics, including vaccines, antiviral drugs, and monoclonal antibodies, is rapidly advancing. Governments and healthcare organizations around the world are investing in Zika virus research, aiming to develop preventive and curative therapies to control future outbreaks and mitigate long-term health risks.

What Are the Key Segments in the Zika Virus Therapeutics Market?

Treatment types include vaccines, antiviral drugs, and antibody-based therapies, with vaccines currently being the most pursued solution. Mode of administration varies from oral medications to injectable treatments, depending on the therapeutic approach. End-users include hospitals, clinics, public health organizations, and research institutions. In terms of geographical distribution, the market is most active in regions with a high incidence of Zika outbreaks, such as Latin America, Southeast Asia, and parts of Africa, although global research efforts are underway to address the virus's potential spread to new regions.

What Technological Innovations Are Driving Advances in Zika Virus Therapeutics?

Technological advancements in vaccine development and antiviral drug research are shaping the future of Zika virus therapeutics. Innovations in genetic engineering, such as the use of RNA-based vaccines, are showing promise in early clinical trials, offering faster and more targeted protection against the virus. Monoclonal antibody therapies are being explored for their potential to neutralize the virus and prevent complications in infected individuals. Additionally, advancements in vector control technologies, such as genetically modified mosquitoes, are being tested as part of an integrated approach to reducing the transmission of the virus. These innovations, combined with improved diagnostic techniques for early detection, are bringing new hope for controlling Zika outbreaks more effectively.

What Factors Are Driving Growth in the Zika Virus Therapeutics Market?

The growth in the Zika virus therapeutics market is driven by several factors, including the increasing global incidence of Zika outbreaks, the rising demand for preventive measures such as vaccines, and advancements in antiviral research. Public health initiatives aimed at controlling vector-borne diseases and the availability of government funding for Zika virus research are also propelling market growth. The urgent need for effective treatments, particularly in regions with endemic transmission, and the focus on preventing long-term health complications are driving investments in developing both preventive and therapeutic solutions. As Zika virus remains a significant global health concern, the demand for effective therapeutics is expected to grow.

Select Competitors (Total 52 Featured) -

• ARUP Laboratories
• Bharat Biotech International Ltd.
• Biocan Diagnostics
• BioVaxys Technology Corporation
• Creative Diagnostics
• Euroimmun AG
• GeneTex
• GeoVax Labs, Inc.
• Inovio Pharmaceuticals, Inc.
• LumiQuick Diagnostics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Zika Virus Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Zika Virus Infections Spurs Demand for Therapeutic Solutions
  • Technological Advancements in Antiviral Drug Development Strengthen Business Case for Zika Virus Therapeutics
  • Increasing Focus on Vaccine Development Expands Addressable Market for Zika Virus Treatments
  • Technological Innovations in Monoclonal Antibody Therapies Enhance Treatment Options for Zika Virus
  • Growing Use of RNA-based Therapeutics in Zika Virus Treatment Expands Market Opportunities
  • Rising Awareness of Zika Virus-related Birth Defects Drives Demand for Preventive Therapeutics
  • Expansion of Global Health Initiatives for Vector Control Strengthens Demand for Zika Therapeutics
  • Technological Advancements in Rapid Diagnostic Kits Spur Demand for Early Treatment Solutions
  • Growing Importance of Public Health Campaigns for Zika Virus Prevention Strengthens Market Demand
  • Technological Innovations in Targeted Delivery Systems for Antivirals Propel Growth in Therapeutics
  • Increasing Demand for Therapeutics in Zika-endemic Regions Expands Market Scope
  • Rising Adoption of Clinical Trials for Novel Antiviral Drugs Strengthens Business Case for Zika Virus Therapeutics
  • Technological Advancements in Genetic Engineering and Vector Control Create Opportunities for Novel Therapeutic Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Zika Virus Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Zika Virus Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Zika Virus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acetaminophen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acetaminophen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Acetaminophen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 11: USA Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 12: USA Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: USA 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 14: Canada Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: Canada Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: Canada 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• JAPAN
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 17: Japan Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Japan Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Japan 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• CHINA
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 20: China Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: China Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: China 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• EUROPE
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 23: Europe Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: Europe Historic Review for Zika Virus Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: Europe 16-Year Perspective for Zika Virus Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• FRANCE
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 29: France Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: France Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: France 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• GERMANY
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 32: Germany Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Germany Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Germany 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 35: Italy Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Italy Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Italy 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 38: UK Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: UK Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: UK 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Rest of Europe Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Rest of Europe 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Zika Virus Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Asia-Pacific Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Asia-Pacific 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Rest of World Historic Review for Zika Virus Therapeutics by Type - Acetaminophen and NSAIDs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Rest of World 16-Year Perspective for Zika Virus Therapeutics by Type - Percentage Breakdown of Value Sales for Acetaminophen and NSAIDs for the Years 2014, 2024 & 2030

IV. COMPETITION